Thursday, 27 June 2013

International Stem Cell to present data from its parkinson's disease program

International Stem Cell Corporation, a California-based biotechnology company developing stem cell based therapies, announced today that it will present preliminary data from its IND-enabling study in Parkinson's disease at the Society for Neuroscience annual meeting in San Diego, CA on November 10th 2013.

The Society for Neuroscience is the world's largest organization of scientists and clinicians devoted to understanding the brain and nervous system. More than 30,000 people are expected to attend the annual meeting, making it one of the largest scientific and medical conferences in the world.

ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC) which are a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. hPNSC are self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (i) differentiate into dopaminergic (DA) neurons and (ii) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson's disease, especially in cases where current small molecule approaches fail to adequately control the symptoms.


No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !